Continuing Education Online - Free CE/CME

Retina Resource

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma - Learning Hub

Stay up to date with the latest advances in hematologic malignancies throug…

23rd Annual School of Breast Oncology® Curriculum

Joyce O’Shaughnessy, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Krish Patel, MD; Girish Kunapareddy, MD

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Krish Patel, MD; Premila Malhotra, MD

Clinical Crossroads™: The Importance of Considering Lambert-Eaton Myasthenic Syndrome (LEMS) in the Differential Diagnosis

Katherine Ruzhansky, MD, MS; Perry Shieh, MD, PhD, FAAN

Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD

From Chair to Care Plan—Applying Evidence to Patient-Centered Management

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

Timing Is Everything—Onset, Duration, and Dosing in Real-World Care

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

From Dropout to Long-Term Wear—A Case-Based Approach to Personalized Contact Lens Care

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

Expanding the Fit—Mastering Toric and Multifocal Success in Complex Patients

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

Mechanism Matters—How OTC Therapies Interrupt the Allergic Cascade

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

Modality Matters—Optimizing Contact Lens Selection for Real-World Wear

Adam Ramsey, OD; Jessilin Quint, OD, MBA, MS, FAAO

Burst CME™ Part VI: What Does this all Mean for Patients with IgAN?

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part V: Complement Inhibitors in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part IV: Anti-CD38 Therapies in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part III: BAFF and APRIL Directed Therapies in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part II: Endothelin A Receptor Antagonists in IgAN

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™ Part I: What’s New in IgAN?

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Burst CME™: Elevating Care in the Management of IgA Nephropathy (IgAN) Nursing Track

Professor Jonathan Barratt, PhD, FRCP; Richard Lafayette, MD

Project ECHO®: CAR T in Practice: Identifying Eligible Patients Across Hematologic Malignancies

Jesús G. Berdeja, MD; Michael Byrne, DO, FACP

Advances in™ Generalized Myasthenia Gravis: Continuing the Quest for Novel Therapies

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisbe…

Cases and Conversations™: Uniting Heart and Kidney Care: Optimizing Outcomes in Cardio-Kidney-Metabolic Disorders

Katherine E. Di Palo, PharmD, MBA, MS; Nancy M. Albert, PhD, APRN-CCNS, CHF…

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD

Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations

Ghassan Abou-Alfa, MD, MBA; Riad Salem, MD, MBA; Rachna Shroff, MD, MS, FAS…

Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC

Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, …

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

Gabriela Hobbs, MD; Rami Komrokji, MD; Douglas A. Tremblay, MD

Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Tina Cascone, MD, PhD; Puneeth Iyengar, MD, PhD; Paula A. Ugalde Figueroa, …

Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham MD, FACP; Paolo Taran…

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Ruben A. Mesa, MD, FACP; Andrew Kuykendall, MD; Sangeetha Venugopal, MD, MS

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, …

The Rapidly Changing Treatment Landscape in the Management of Atopic Dermatitis—A Place in Therapy for OX40-OX40L Inhibitors

Andrew Blauvelt, MD, MBA; Melinda Gooderham, MD, FRCPC

Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; Ja…

BURST CME™ Activity 1: Foundations of Endocrine Resistance and Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Adam Brufsky, MD, PhD; Manali Bhave, MD

Beyond the Itch—Decoding the Immunopathology of Allergic Conjunctivitis

Walter Whitley, OD, MBA, FAAO; Cecelia Koetting, OD, FAAO, DipABO

BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base

Adam Brufsky, MD, PhD; Manali Bhave, MD

Practical Strategies for Monitoring and Managing Toxicities With Novel Therapies for HER2-Positive Gastroesophageal Adenocarcinoma

Samuel J. Klempner, MD, FASCO; Christian Baglini, MS, AGNP-BC; Jonathan N. …

Oncology Town Hall: Updates From Chicago: Oral SERDs in HR+/HER2− Metastatic Breast Cancer–What the Latest Data Really Tell Us

Virginia Kaklamani, MD, DSc; Kamel Abou Hussein, MD; Javier Cortés, MD, PhD…

Obesity: New and Emerging Strategies to Optimally Manage a Chronic Disease

Scott Kahan, MD, MPH; Robert F. Kushner, MD, MS, DABOM; Christopher D. Stil…

Selecting an Optimal Therapeutic Strategy for the Management of Atopic Dermatitis in Young Children

Elaine Siegfried, MD; Lawrence F. Eichenfield, MD

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro…

Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Lori A. Leslie, MD; Bachar Samra, MD

PER Global Perspectives: Preparing for the Emergence of TROP2 ADCs With Immunotherapy in the Earlier Treatment Settings

Solange Peters, MD, PhD; Myung-Ju Ahn, MD, PhD; Luis Paz-Ares, MD, PhD; Jac…

Rapid Reviews in Retina™: 2026 Updates – Episode 1: nAMD

Anat Loewenstein, MD

Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer—What the Latest Data Really Tell Us

Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Heather McArthur, MD, MPH;…